<?xml version="1.0" encoding="UTF-8"?>
<p>Since these early studies, which generated alarm in the public media as well as scientific debate [
 <xref rid="pntd.0007060.ref027" ref-type="bibr">27</xref>â€“
 <xref rid="pntd.0007060.ref029" ref-type="bibr">29</xref>], there has been no systematic review or meta-analysis that has synthesized all available in vivo human and higher order animal evidence and provided a current consensus on whether prior DENV infection is indeed a risk factor for worsened ZIKV clinical outcomes such as GBS, CZS or whether prior DENV exposure changes possible laboratory proxies of severity such as ZIKV viremia or inflammatory cytokine profiles. Resolving this question is critical for both clinical prognosis of those with ZIKV infection as well as DENV vaccine implementation in areas endemic to both ZIKV and DENV [
 <xref rid="pntd.0007060.ref028" ref-type="bibr">28</xref>].
</p>
